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Cross-entropyin multiple types of cancers is of signiﬁcant therapeutic importance. We show
that collective evidence for such genes can be obtained via a form of meta-analysis that aggregates the results
(rankings and p values) from various cancer-speciﬁc microarray experiments. This method is illustrated by a
combined analysis of 20 microarray experiments. In the aggregated list of top-50 genes, 36 of them have
been implicated in cancer (often multiple cancers) genesis in past studies, which also suggests that this list
may contain some novel cancer genes that may deserve further scrutiny in the future.
© 2008 Elsevier Inc. All rights reserved.Learning fromsmall-scale experiments, biologists have known for a
long time of certain genes that are risk factors for multiple cancers.
Identiﬁcation of such genes is most important because targeting them
could lead to prevention of many types of cancer. These genes include
both oncogenes, which are ampliﬁed in cancers and activate the
growth of tumors across different organs, and tumor suppressor genes,
which have the opposite effect and, if active, prevent multiple types of
tumor growth and development. For example, the oncogene PIK3CA
belonging to the PI3K pathway has been implicated in numerous
cancers [1,2], in particular ovarian, colorectal, and endometrioid
cancers [3]. Similarly, p53, which is a tumor suppressor gene whose
activity prevents formation of tumors, clearly affects multiple cancers
because of its fundamental role in tumor suppression [4,5]. Recently,
Bagchi et al. [6] discovered a novel tumor suppressor gene, CHD5, and
suggested that it could be a target for multiple cancer prevention.
The majority of cancer microarray experiments, however, are
designed around a speciﬁc cancer type. By comparing gene expression
levels between tumor and healthy samples, researchers can identify
signiﬁcantly differentially expressed genes that are usually system-
speciﬁc andmay not necessarily be implicated in other types of cancer.
However, to put some of these genes into a greater perspective and
construct an overall picture of the common genetic factors across
multiple types of cancer, muchmore data needed to be collected. Thus
it is perhaps not surprising that the surge in the numbers ofmicroarray
experiments in the last several years presented an opportunity for
researchers to answer the question of the involvement of commonr),
louisville.edu (S. Datta).
l rights reserved.genes in multiple cancers in a more systematic way by means of
microarray data meta-analysis [7–9].
Meta-analysis of microarray data coming from a number of
microarray experiments can be attempted with two systematically
different approaches. Although it is obvious that some sort of
aggregation of the results is necessary to accomplish this, enough
ﬂexibility is left regarding what is aggregated and at what stage. In the
ﬁrst approach, different microarray experiments are put together to
form a single dataset that can be analyzed as a separate entity without
considering the origin of each sample (see, e.g., [10]). Performing a
cluster analysis on a set of probe IDs (genes) based on their expression
proﬁles created as a result of such aggregation of microarray experi-
ments is a perfect example of the ﬁrst approach. In the second approach,
however, instead of aggregating expression values (combining micro-
array samples directly), each individual microarray experiment is
analyzed ﬁrst and then the statistical results from all experiments are
aggregated to produce the ﬁnal meta-analysis results [11].
In this work we follow the second approach in which we combine
the statistical evidence of differential expressions across various tissue
types (e.g., normal and various gradations of cancer) from 20 different
cancer experiments. Our aggregation uses both the rank orders of each
gene (in terms of its statistical signiﬁcance) and the (appropriately
scaled) magnitude of the actual p values in each experiment. An
advantage of our method is that it is applicable even when the
individual experiments were run using different microarray platforms
as long as a common set of candidate genes could be identiﬁed and
then be subjected to the meta-analysis (rank aggregation).
The rank aggregation is formulated as awell-deﬁnedminimization
problem in terms of decision theory, which is then solved by the cross-
entropy algorithm (originally due to [12]). The usefulness of the cross-
entropymethod for the rank aggregation problem and other biological
Fig. 1. The distribution of the top-50 genes from our overall list. The height of each bar
represents the number of times (out of 20) each gene appears in individual top-50 lists.
401V. Pihur et al. / Genomics 92 (2008) 400–403applications was recognized by Lin et al. [13] and Pihur et al. [14]. The
remarkable property of this algorithm is that it is capable of
performing the necessary stochastic search in a rather large space of
possible lists. (Its size was of the order of 10148 for our problem!)
In the next section, we report a list of 50 genes (in this work we
loosely use “genes” for probe IDs) that are judged to be the most
differentially expressed overall in these experiments when the
rankings in terms of p values are aggregated. This includes a gene
coding for a transmembrane anchor protein, MXRA7, which appeared
in the top-50 list of three individual microarray experiments that we
aggregated. The resulting top-50 list contains 36 genes that have been
implicated in cancer (often in more than one cancer type) in the
literature. The remaining genes are novel in terms of their connection
to cancer (as mined from the existing literature). The current analysisTable 1
Top-8 probe IDs from the combined list
Probe ID Symbol GO processes Kegg pathways
217294_s_at ENO1 Negative regulation of cell
growth, glycolysis, regulation
of transcription
206283_s_at TAL1 Regulation of transcription, cell
proliferation, cell differentiation
HSA04310: wnt signa
pathway
201014_s_at PAICS Purine base biosynthetic process,
de novo IMP biosynthetic process
212509_s_at MXRA7 Integral to membrane
206701_x_at EDNRB G-protein signaling, coupled to IP3
second messenger, signal transduction,
peripheral nervous system development
HSA04020: calcium s
pathway, HSA04080:
ligand-receptor inter
203184_at FBN2 Anatomic structure morphogenesis pancreatic cancer
212143_s_at IGFBP3 Positive regulation of myoblast
differentiation, regualtion of cell
growth, positive regulation of apoptosis
212932_at RAB3GAP1 Regulating GTPase activity
All but the last one have been implicated in playing a role in different cancers in the past. Psuggests that perhaps they should be investigated further for their
regulatory roles related to cancer activities.
Results
For each of the 20 microarray datasets, we obtain a top-50 list of
probe IDs ranked according to their p values from an ANOVA analysis.
The lists along with the corresponding p values, which play the role of
weights, is then used to produce a single combined top-50 list via the
weighted rank aggregation approach mentioned in the previous
section. Further details of this procedure appear later in the article.
Applying the rank aggregation procedure to the 20 top-50 lists
produces the following overall top-50 (ordered) gene list:
ENO1, TAL1, PAICS, MXRA7, EDNRB, FBN2, IGFBP3, RAB3GAP1, CA4,
DLC1, HGF, CYP3A5, GOLM1, HOXA10, HOXA5, PRKAR2B, LDLR, ANXA8L1,
CYP3A5P2, PSD3, FLRT3, STAB1, SFRP1, TFDP2, KRT5, TFDP2, ID4, SFRP1,
SPAG6, C20ORF103, CD9, NXF3, SDCBP, CFP, CTBP2, CSDA, FAM107A,
PROL1, SPTBN1, KANK3, HLX1, AGER, CA4, LRRN3, AGER, SGCG, GRIA1,
GPM6A, ASPA, TEX14.
In Fig. 1, a barplot shows the total number of times each gene in the
aggregated list appears within the 20 individual lists. The maximum
number of lists that any gene appeared inwas 3; only one gene,MXRA7,
which codes for a transmembrane anchor protein, attained this. De-
spite the fact that the microarray experiments were related, the
majority of genes were on only one top-50 list. This small overlap
between the individual top-50 lists may be surprising at ﬁrst, but
perhaps it is not unusual because the number of genes in each
experiment is rather large. Indeed, DeConde et al. [11] observed similar
patterns, where they aggregate ﬁve top-25 lists obtained from ﬁve
microarray datasets (all prostate cancer). In their example, individual
lists contained 89 unique genes, of which 23 appearedmore than onceOncology PubMed
ID
Description
Breast
carcinoma
7641187 Negative regulatory function by down-
regulating c-myc expression
9074493 Transcriptional repressor activity on c-myc
promoter
Cervical
carcinoma
7641187
Lung
carcinoma
10853020
Carcinoma 11973636 Selectively represses Bcl-xL expression in
MCF-7 cells and induces mitochondrial
involvement in the apoptotic process
ling t-all 9695959 Disrupted by translocation or deletion
(tal(d)) in up to 30% of T-cell acute
lymphoblastic leukaemia (T-ALL)
8208530
Leukemia 2040693 tal-1 rearrangements
Cancer 17224163 This study provides essential structural
information for designing PAICS-speciﬁc
inhibitors for use in cancer chemotherapy
Lung
carcinoma
15246564
MRD 16627760 Tissue matrix remodeling-like gene
ignaling
neuroactive
action
Bladder cancer 15569975
15951052 Loss of FBN2 expression due to promoter
methylation was recently identiﬁed in
pancreatic cancer
Breast cancer 8609661 Involved in the regulation of breast cancer
cell growth
10067859
ubMed IDs are given for further references.
402 V. Pihur et al. / Genomics 92 (2008) 400–403and only one gene appeared in all ﬁve lists. This also suggests that a
visual inspection of the individual top-50 list will not be enough to
form the overall ranking of the top-50 genes and a mathematical
procedure such as the one proposed here is needed to achieve this.
The full table is provided in Appendix A: Supplementary material.
It shows the list of overall top-50 genes along with their Go biological
functions mined through Osprey [15], Kegg pathways mined through
David [16], and oncological implications with relevant PubMed IDs for
the most part identiﬁed through Gene Cards available at http://www.
genecards.org. In Table 1 we show the ﬁrst 8 probe IDs from the larger
table on the supplementary website.
Thirty-six of the ﬁfty genes on our aggregated list have been
previously implicated in different cancers, many of them, as we would
expect, in multiple cancers. The ﬁrst gene on the list, ENO1, which is
responsible for the negative regulation of cell growth among its other
functions, has been previously implicated in breast, cervical, and lung
cancers. Please refer to Table 1 for the PubMed IDs of the relevant
articles. Other genes at the top list, such as TAL1, PAICS, EDNRB, FBN2,
and IGFBP3, have been associated with at least one form of cancer.
Existing evidence in the literature suggests that gene CYP3A5 (12 on
our list) is linked with leukemia, prostate, breast, and colorectal
cancers. Gene 14, HOXA10, plays a role in multiple forms of leukemia
and endometrial cancer. Many more examples of genes' involvement
in multiple cancers can be found. Gene AGER represented by probe IDs
42 and 45 appearing toward the end of the list claims partial
responsibility for lung, colorectal, prostate, and pancreatic cancers.
Not all of the genes in our list have been previously associated with
any form of cancer. These remaining 14 genes, among which are
RAB3GAP1, GOLM1, ANXA8L1, and CYP3A5P2, may have to be further
studied in connectionwith cancer development. For most of them, not
much biological information in the form of Go annotations and path-
ways is available at present.
We ran the aggregation method three times with different starting
seeds for the Monte Carlo sampler and each time obtained a slightly
different aggregated list. Looking at the values of the objective
function for each resulting list, we noted that the difference among
them was less than 0.033%. In the above, we reported the list
corresponding to the lowest value of the objective function out of the
three. The algorithm converged in 47 iterations. The lists were very
similar in terms of which probe IDs were included (at least 40 probe
IDs from the reported list were included in the other two lists) but
differed in the actual ordering, especially at the tail ends. It is perhaps
not surprising that multiple runs of the stochastic cross-entropy
algorithm do not produce identical ordered lists, especially given that
the size of the search space is extremely large.
Alternative aggregation methods
For the purpose of ﬁnding the optimal solution to this minimization
problemwealso tried thegenetic algorithm(GA), but it failed to converge,
probably because itwasunable to successfullyexplore the search space of
this size (10148). Both CE and GA algorithms for our weighted rank
aggregation are implemented in an R package, RankAggreg, publicly
available on CRAN (the Comprehensive R Archive Network).
In addition, we implemented one of the rank aggregation
algorithms discussed in [11], namely, theMCTalgorithm, and obtained
an aggregated list. A comparisonwith the list obtained from the cross-
entropy algorithm revealed 16 probe IDs in common. It is important to
note, however, that the MCT algorithm does not take into considera-
tion the p values obtained from the F tests (or t tests) according to
which the individual lists themselves are ordered.
Discussion
The weighted rank aggregation method based on the cross-
entropy Monte Carlo algorithm proves to be a useful tool for carryingout meta-analysis of microarray experiments. Top-k lists of genes, the
usual results of microarray analyses, can be successfully aggregated to
form a single list of genes based on multiple experiments. Here we
limit our investigation to k=50. A larger list can also be produced at a
greater computational cost.
Using cross-entropy Monte Carlo algorithms with Spearman's
footrule distance as a measure of “closeness” between two ordered
lists is one of themany possible approaches to rank aggregation. Itmust
be noted here that the problem of rank aggregation has a long history,
which has its origins in voting theory. The Borda count is probably the
most famous and intuitive rank aggregation scheme in which each
element in each ordered list is given a score depending on its rank and
then theseweights are summed up across all such lists. Elements in the
aggregated list are given in descending order according to the overall
scores. An alternative to the Borda count, the Condorcet method, can
also be considered. It performs aggregation based on the number of
pairwisewins of eachelement. Themorewins, the higher the ranking in
the ﬁnal list. These two approaches represent the competing philoso-
phies on rank aggregation. While the Borda count seeks “consensus”
among the lists to be ordered andwill usually ensure that elements that
are consistently at the top of individual lists surface to the top of the
aggregated list, the Condorcet method gives the advantage to elements
favored by the majority of the lists, neglecting the few where these
particular elements are ranked at the very end.
Both Borda and Condorcet methods can be easily applied when the
ordered lists to be aggregated are mere permutations of each other.
When this is not the case, aswith our ordered lists of genes, both Borda
scores and pairwise wins will result in a very large number of ties that
cannot be easily resolved. This is one reason our method for rank
aggregation makes use of additional information available in the form
of weights (p values, in this case), which virtually eliminate the
possibility of such ties. The second advantage of the rank aggregation
method implemented here is the formal framework of a well-deﬁned
minimization problem, which has more appeal than somewhat
arbitrary criteria of both the Borda and Condorcet methods. This
rank aggregation can also be extended by considering different
distance measures between lists, for example, Kendell's tau distance.
As shown here the cross-entropy algorithm is suitable for solving the
underlying optimization problem.
Materials and methods
Meta-dataset
In this article, we describe our analysis of part of the challenge dataset (meta-
analysis dataset) for CAMDA 2007. This contest meta-analysis microarray dataset
consists of 5897 arrays collected from approximately 250 individual microarray
experiments that study the whole range of different conditions in humans. All of the
individual microarray studies were hybridized with the Affymetrix GeneChip Human
Genome HG-U133A and record expression levels for 22,283 probe IDs.
The goal of our meta-analysis is to identify genetic factors that are common across
different types and stages of cancer. For that purpose, we selected 20 different cancer-
related microarray experiments (leukemia, neuroblastoma, thyroid carcinoma, lung
cancer, prostate cancer, breast cancer, and some other tissues) that are included in the
contest meta-dataset and have explicit cell type groupings necessary for detecting
differentially expressed genes. Here, we list the selected experiment IDs along with the
number of samples in each experiment in parentheses: E-MEXP-72 (20), E-MEXP-83
(22), E-MEXP-76 (17), E-MEXP-97 (24), E-MEXP-121 (30), E-MEXP-149 (20), E-MEXP-
231 (58), E-MEXP-353 (96), E-TABM-26 (57), E-MEXP-669 (24), GSE4475 (221),
GSE1456 (159), GSE5090 (17), GSE1420 (24), GSE1577 (29), GSE1729 (43), GSE2485
(18), GSE2603 (21), GSE3585 (12), GSE4127 (29). The total number of selected arrays is
941 (about 1/6 of the overall number of samples in the meta-dataset). One can refer to
ArrayExpress database, which provides public access to the microarray data from these
experiments (http://www.ebi.ac.uk/arrayexpress/).
Rank aggregation
The proposed meta-analysis approach to microarray data is a two-step procedure:
(1) Individual analysis. By analyzing each microarray dataset individually, a set of
“interesting” genes (top-50 probe IDs) that exhibit the largest differences in terms
of expression values between the groups is obtained for each dataset.
403V. Pihur et al. / Genomics 92 (2008) 400–403(2) Rank aggregation. Aggregation of the individual lists from Step 1 based on the
rankings of genes within each list is performed to produce a “super” list of 50 probe
IDs which would reﬂect the overall importance of genes (and their order of
importance) as judged by the collective evidence of all experiments.
In the ﬁrst step, one-way ANOVA analysis is performed on each probe ID for each
dataset (20 in our case). The usual F test statistic and the corresponding p value are
computed for each probe ID. The smaller the p value, the stronger the evidence for the
involvement of the corresponding probe ID in cancer-related processes. If we rank
probe IDs according to the p values assigned by ANOVA from the smallest to the largest,
the top most probe IDs are of primary interest to biologists as revealed through that
microarray experiment. These individual ranked lists can be combined to produce a
top-k list using the rank aggregation method provided in [14]. In the present context it
can be expressed as the following optimization problem. Find the aggregated ordered
list δ⁎ that minimizes
∑
M
d δ; LMð Þ;
whereM indices the microarray experiments, LM are the ordered lists to be combined, δ
is any ordered list of size k=|LM|, and d is a distance function which, in our case, is the
weighted Spearman footrule distance to be deﬁned next.
Let p(1,M),…,p(k,M) be the p values corresponding to the top-k probe IDs and rLM(G)
be the rank of probe ID G underM (1 means “best”) if G is within top k, and be equal to
k+1, otherwise. The weighted Spearman footrule distance then can be deﬁned as
d δ; LMð Þ ¼ ∑
taLM[δ
jp rδ tð Þ;M −p rLM tð Þ;M jjrδ tð Þ−rLM tð Þj:
The above optimization problem is solved using the cross-entropy Monte Carlo
algorithm proposed by Rubinstein for solving large combinatorial optimization
problems [12]. An ordered list of k out of n genes is expressed as an n×k matrix of
entries 0 and 1 satisfying certain constrains and a stochastic search is conducted in a
sequential manner. In our analysis reported here, k=50 and n=966 is the number of
unique probe IDs in the union of the 20 top-50 lists. We omit further details of the CE
algorithm as they can be found in the earlier papers (e.g., [17,13,14]).
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